We describe the success of adjunctive bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection in the context of bilateral ureteric stents and bladder ulceration, after repeated failure of antibiotics alone. No bacteriophage-resistant bacteria arose, and the kinetics of bacteriophage and bacteria in urine suggest self-sustaining and self-limiting infection.
Introduction
Pseudomonas aeruginosa is an opportunistic human pathogen associated with biofilm infections refractory to antibiotic therapy, particularly in cystic fibrosis and burn wounds and in other immunocompromised hosts (Azeredo & Sutherland, 2008; Fothergill et al., 2010) . Lytic bacteriophage has long been known to have the potential to deliver effective targeted therapy (Himmelweit, 1945) , including for P. aeruginosa, and increasing antibiotic resistance has sparked renewed interest in this approach (Azeredo & Sutherland, 2008; Kutter et al., 2010; Harper & Enright, 2011) .
Case report
A 67-year-old woman underwent extensive intra-abdominal resections and pelvic irradiation for adenocarcinoma followed by bilateral ureteric stent placement to relieve obstruction. This was complicated by symptomatic P. aeruginosa infection, for which she received multiple courses of gentamicin, ceftazidime, ciprofloxacin and meropenem over a 2 year period, and two stent replacements. Symptomatic relapse with P. aeruginosa susceptible to ciprofloxacin (MIC 0.25 mg ml 21 ), gentamicin (2 mg ml 21 ), ceftazidime (4 mg ml
21
) and meropenem (MIC 2 mg ml
; determined by Etest performed according to manufacturer's instructions; Etest, AB bioMérieux) occurred usually within a week after ceasing antibiotics, always at .10 5 c.f.u. ml 21 and in association with pyuria (.100 white blood cells ml
) and haematuria.
Several isolates of the infecting P. aeruginosa strain were screened against existing bacteriophage libraries at the Eliava Institute in Tbilisi (Democratic Republic of Georgia, DPR) which have been used extensively to treat patients (Kutter et al., 2010; Stone, 2002) . Six lytic bacteriophages, each at a titre of 10 6 p.f.u. ml 21 against the target P. aeruginosa, were combined into a filter-sterilized bacteriophage product (Pyophage #051007) licensed under DPR Ministry of Health guidelines (Stone, 2002; Sulakvelidze et al., 2001) . Routine bacterial culture on chocolate agar (Difco) at 37 u C of a sample vial was again negative in the Centre for Infectious Diseases and Microbiology Laboratory Services laboratory.
Ethical approval was obtained from the Western Sydney Human Research Ethics Committee on a compassionate use basis, and informed consent was obtained from the patient. The patient was hospitalized and 20 ml (~2610 7 p.f.u.) Pyophage # 051007 was instilled directly into the bladder every 12 h for 10 days, with the catheter clamped for 30 min after each instillation. Urine was collected before treatment and at 4 h intervals after the morning dose for the first 2 days, and then each morning prior to bacteriophage and antibiotic treatment. The catheter was changed on days 3 and 10. Meropenem (1 g twice daily) and colistin (polymixin E, 100 mg twice daily) commenced on day six. Colistin was used for a total of 5 days (days 6-10) and the patient was discharged home on intravenous meropenem alone after day 10, to complete a total meropenem course of 30 days.
Both stents were removed for a third time and the right ureteric stent was reinserted while still on meropenem (day 20). Cystoscopy at that time revealed an inflamed bladder with bilateral lower ureteric strictures and an ulcerated bladder base. Midstream urine sampled every 8 weeks remained sterile for 6 months after completion of antibacterial treatment, during which time the patient remained asymptomatic. Intermittent haematuria continued but no further antibiotic therapy was used. Urine cultures were negative when the patient was admitted with recurrent intra-abdominal malignancy a year later.
Microbiological studies
For quantifying bacteriophage in urine, samples were diluted 1 : 1 in 0.9 % (w/v) PBS, filtered through a 0.2 mm filter and evaluated in an overlay assay with the relevant P. aeruginosa strain. All assays were performed in triplicate. Serial dilutions of urine were also incubated aerobically on blood agar (Oxoid) at 37 uC for bacterial colony counts. All P. aeruginosa and Enterococcus faecalis isolates were tested against the bacteriophage cocktail: 100 ml~10 6 c.f.u. exponential phase organisms ml 21 in 3 ml 0.4 % nutrient agar (NA; Difco) at 50 u C was overlaid onto 0.8 % NA and allowed to solidify at 25 u C for 20 min; 5 ml bacteriophage serially diluted in modified Tris buffer [5 ml 2 % (w/v) gelatin in 50 ml 1.0 M Tris/HCl (pH 7.0) with 5.8 g NaCl l
21
, 2.0 g MgSO 4 .7H 2 O l 21 ] was adsorbed into the overlay. Plaques were counted after 18 h aerobic incubation at 37 u C. To establish the frequency of resistance to bacteriophages after the therapeutic intervention, the bacteriophage preparation was applied as above in 10-fold dilutions (neat to 1 : 10 4 ) onto bacterial lawns prepared from phage-treated samples days 1, 3 and 7. Bacteriophage was enumerated in urine by dilution as above. All assays were performed in triplicate.
Two hundred microlitre aliquots of urine were also extracted (GenElute Mammalian DNA Extraction kit; Sigma-Aldrich) for bacterial DNA load estimation, as were control strains (suspended at~10 3 c.f.u. ml 21 in sterile 0.9 %, w/v, NaCl). The 16S rDNA of Enterobacteriaceae, Pseudomonas species, Enterococcus species, Streptococcus species and Staphylococcus species was quantified by multiplexed tandem PCR (MT-PCR) (Bacterial Count; AusDiagnostics), essentially as previously described (Szewczuk et al., 2010) , in a RotorGene RG6000 cycler (Corbett Research). Limits of detection were determined as the means of three different experiments using sterile urine spiked with P. aeruginosa ATCC 27853 (183 c.f.u. ml Antibiotics were present from day 6 after pre-dose sampling (bold). A. Khawaldeh and others Fig. 1 . Logarithmic plot of early morning urine viable P. aeruginosa (c.f.u. ml "1 ) and bacteriophage (p.f.u. ml "1 ) counts. Antibiotic administration and catheter change and removal (days 3 and 10, respectively; boxed) are indicated.
